

## BÖLÜM 8

# DİRENÇLİ GRAM NEGATİF ENFEKSİYONLARIN TEDAVİSİNDE ANTİBİYOTİKLERİN ALTERNATİF KULLANIM YÖNTEMLERİ

Uzm. Dr. Belgin Coşkun

*Ankara Şehir Hastanesi Enfeksiyon Hastalıkları ve  
Klinik Mikrobiyoloji Kliniği, Ankara*

### 8.1. GİRİŞ

Enfeksiyon hastalıklarının tedavisinde kullandığımız en önemli silah şüphesiz ki antibiyotiklerdir. Ancak antibiyotiklerin uygunsuz kullanımları direnç gelişimini artırarak, mikroorganizmalarla mücadeleyi zorlaştırmaktadır. Özellikle 2000’li yıllardan bu yana artan antibiyotik direnci, yeni antibiyotiklerin keşfinin kısıtlı olması nedeni ile elimizdeki antibiyotikleri farklı yollarla kullanmaya itmiştir. Amaç, kısa sürede hedef bölgede yüksek doz antibiyotik uygulamasını sağlayarak, “Minimal inhibitör konsantrasyon” (MİK) değeri yüksek mikroorganizmalara bile etki etmektir. Hedef bölgeye yönelik antibiyotik uygulamaları, hedef bölgede yüksek dozda antibiyotik konsantrasyonu sağlamanın yanında, antibiyotiklerin sistemik yan etkilerinden de vücudu korumaktadır. Birçok antibiyotik kullanım yolları olmakla birlikte, dirençli mikroorganizmaların tedavisi için önerilen inhaler, intratekal/intraventriküler, intravezikal ve intraplevral uygulamalar bu bölümde sırasıyla ele alınacaktır.

### 8.2. İnhaler antibiyotik kullanımı

Havada asılı olarak kararlılığını koruyan küçük çaplı katı partiküllerin ve sıvı damlacıkların gaz içerisinde dağılması ile meydana gelen kolloid sistemlere “aerosoller” denir. Aerosol ilaç kullanılarak yapılan tedavilere de inhaler tedaviler denir. İnhalasyon yolunun kullanılmasının en önemli avantajı hedef dokuda etkinliğinin yüksek, yan etkilerinin az olmasıdır. En önemli dezavantajı ise, ilaç uygulamasının birçok faktörden etkilenmesidir. Hastaya bağlı olan, mukus tıkaç varlığı, akciğer kapasitesi, tidal volüm, solunum sayısı, bronkokonstirüksiyon varlığı gibi birçok faktörden etkilenirken, mekanik ventilatöre bağlı hastalarda da, ventilatöre, cihaza, devreye ilişkin bir çok faktör devreye girer (1). “Food and

sistemik antibiyotik tedavisi uygulanmıştır. Çalışma sonucunda tüm hastalarda tedavi yanıtı izlendiği ve rekürrens gelişmediği belirtilmiştir (44).

Sonuç olarak intraplevral antibiyotik uygulaması ampiyem tedavisinde tüp drenajı ve sistemik antibiyotik tedavisine ek olarak uygulanabilecek bir yöntemdir. Ancak standardizasyonunun sağlanabilmesi ve günlük kullanıma girebilmesi için daha çok deneyime ve randomize kontrollü çalışmalara ihtiyaç vardır.

## **KAYNAKLAR**

1. Aygencel G. İnhaler Antibiyotik Kullanımı. In: Dizbay M, editor. Antimikrobiyal Uygulamaları. Ankara, Türkiye: Bilimsel Tıp Yayınevi; 2017.
2. Mearns MB, Hunt G, Rushworth R. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-1971. Archives of disease in childhood. 1972;47(256):902-7.
3. Farber JE, Ross J. The use of aerosol penicillin and streptomycin in bronchopulmonary infections. California medicine. 1950;73(3):214.
4. Kuhn RJ. Formulation of aerosolized therapeutics. Chest. 2001;120(3):94S-8S.
5. Feeley TW, Du Moulin G, Hedley-Whyte J, Bushnell L, Gilbert J, Feingold D. Aerosol polymyxin and pneumonia in seriously ill patients. New England Journal of Medicine. 1975;293(10):471-5.
6. Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled antibiotics for Gram-negative respiratory infections. Clinical microbiology reviews. 2016;29(3):581-632.
7. Le J, Ashley E, Neuhauser M, Brown J, Gentry C, Klepser M, et al. Wood GC Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2010;30(6):562-84.
8. Kuhn RJ. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2002;22(3P2):80S-5S.
9. Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Critical care. 2006;10(4):R123.
10. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Critical care medicine. 2008;36(7).
11. Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surgical infections. 2007;8(1):73-82.
12. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clinical infectious diseases. 2010;51(11):1238-44.
13. Korbila I, Michalopoulos A, Rafailidis P, Nikita D, Samonis G, Falagas M. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clinical microbiology and infection. 2010;16(8):1230-6.
14. Le PC, Potel G, Clementi E, Legras A, Villers D, Bironneau E, et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse medicale (Paris, France: 1983). 2000;29(2):76-8.
15. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwina N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. Journal of antimicrobial chemotherapy. 2010;65(12):2645-9.

16. Doshi NM, Cook CH, Mount KL, Stawicki SP, Frazee EN, Personett HA, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. *BMC anesthesiology*. 2013;13(1):45.
17. Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. *Chest*. 2013;144(6):1768-75.
18. Brown R, Kruse J, Counts G, Russell J, Christou N, Sands M. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. *Antimicrobial agents and chemotherapy*. 1990;34(2):269-72.
19. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*. 2016;63(5):e61-e111.
20. EYÜBOĞLU FÖ. Erişkinlerde Hastanede Gelişen Pnömoni Tanı ve Tedavisi Uzlaş Raporu. In: EYÜBOĞLU FÖ, editor. *Türk Toraks Derneği Erişkinlerde Hastanede Gelişen Pnömoni Tanı ve Tedavisi Uzlaş Raporu*2018.
21. Shah SS, Ohlsson A, Shah VS. Intraventricular antibiotics for bacterial meningitis in neonates. *Cochrane Database of Systematic Reviews*. 2012(7).
22. Wen DY BA. Infections in neurologic surgery. The intraventricular use of antibiotics. *Neurosurg Clin N Am*. 1992;3:343-54.
23. Bargiacchi O, De Rosa FG. Intrathecal or intraventricular colistin: a review. 2016.
24. Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. *Clinical Infectious Diseases*. 2017;64(6):e34-e65.
25. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant *Acinetobacter baumannii* central nervous system infection: a case series and systematic review. *Clinical microbiology and infection*. 2010;16(7):888-94.
26. Ziaka M, Markantonis SL, Fousteri M, Zygoulis P, Panidis D, Karvouniaris M, et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. *Antimicrobial agents and chemotherapy*. 2013;57(4):1938-40.
27. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clinical infectious diseases*. 2012;55(7):943-50.
28. Molinaro M, Morelli P, De Gregori M, De Gregori S, Giardini I, Tordato F, et al. Efficacy of intraventricular amikacin treatment in pan-resistant *Pseudomonas aeruginosa* postsurgical meningitis. *Infection and drug resistance*. 2018;11:1369.
29. Hasan Selçuk Özger MD. İntratekal/İntraventriküler İlaç Uygulamaları. *Antimikrobiyal Uygulamaları*2017. p. 79-101.
30. Brown JdL, R. Bayston, P. D Lees, IK Pople, EM. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. *British journal of neurosurgery*. 2000;14(1):7-12.
31. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clinical infectious diseases*. 2010;50(3):291-322.
32. Ömer Karaşahin MD. İntravezikal Antimikrobiyal İlaç Uygulamaları. *Antimikrobiyal Uygulamaları*2017.
33. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clinical infectious diseases*. 2010;50(5):625-63.

34. McGuire EJ, Savastano JA. Treatment of intractable bacterial cystitis with intermittent catheterization and antimicrobial instillation: case report. *The Journal of urology*. 1987;137(3):495-6.
35. Rhame FS, Perkash I. Urinary tract infections occurring in recent spinal cord injury patients on intermittent catheterization. *The Journal of urology*. 1979;122(5):669-73.
36. Tuon FF, Amato VS, Penteado Filho SR. Bladder irrigation with amphotericin B and fungal urinary tract infection—systematic review with meta-analysis. *International journal of infectious diseases*. 2009;13(6):701-6.
37. Hajar RR, Philpot C, Morley JE. CONTINUOUS BLADDER IRRIGATION WITH VANCOMYCIN FOR THE TREATMENT OF METHICELUN-RESISTANT STAPHYLOCOCCUS AUREUS. *Journal of the American Geriatrics Society*. 1996;44(7):886-7.
38. Hill DM, Wood GC, Hickerson WL. Linezolid bladder irrigation as adjunctive treatment for a vancomycin-resistant *Enterococcus faecium* catheter-associated urinary tract infection. *Annals of Pharmacotherapy*. 2015;49(2):250-3.
39. Fernandez PAV, Rodríguez CF, Cornejo-Juárez P. Intravesical colistin irrigation to treat multidrug-resistant *Acinetobacter baumannii* urinary tract infection: A case report. *Journal of Medical Case Reports*. 2012;6:426.
40. Salehipour M, Salah H, Fathikalajahi A, Mohammadian R, Emadmarvasti V, Bahador A, et al. Is perioperative intravesically applied antibiotic solution effective in the prophylaxis of urinary tract infections after renal transplantation? *Urologia internationalis*. 2010;85(1):66-9.
41. Pietropaolo A, Jones P, Moors M, Birch B, Somani BK. Use and effectiveness of antimicrobial intravesical treatment for prophylaxis and treatment of recurrent urinary tract infections (UTIs): a systematic review. *Current urology reports*. 2018;19(10):78.
42. Yetkin MA. İntralevral Antibiyotik Uygulaması. *Antimikrobiyal Uygulamaları*2017. p. 113-8.
43. Bagan P, Boissier F, Berna P, Badia A, Le Pimpec-Barthes F. Postpneumonectomy empyema treated with a combination of antibiotic irrigation followed by videothoracoscopic debridement. *Journal of thoracic and cardiovascular surgery*. 2006;132(3):708-10.
44. Ng T, Ryder BA, Maziak DE, Shamji FM. Treatment of postpneumonectomy empyema with debridement followed by continuous antibiotic irrigation. *Journal of the American College of Surgeons*. 2008;206(6):1178-83.